Omni Bio Pharmaceutical (OTCMKTS:OMBP) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.
Volatility & Risk
Omni Bio Pharmaceutical has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, Organovo has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.
This table compares Omni Bio Pharmaceutical and Organovo’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Omni Bio Pharmaceutical||N/A||N/A||N/A|
Valuation and Earnings
This table compares Omni Bio Pharmaceutical and Organovo’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Omni Bio Pharmaceutical||N/A||N/A||N/A||N/A||N/A|
|Organovo||$4.60 million||28.05||-$34.80 million||($0.32)||-3.38|
Omni Bio Pharmaceutical has higher earnings, but lower revenue than Organovo.
Institutional and Insider Ownership
36.2% of Organovo shares are held by institutional investors. 3.5% of Organovo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current recommendations for Omni Bio Pharmaceutical and Organovo, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Omni Bio Pharmaceutical||0||0||0||0||N/A|
Organovo has a consensus price target of $2.13, suggesting a potential upside of 96.76%. Given Organovo’s higher probable upside, analysts clearly believe Organovo is more favorable than Omni Bio Pharmaceutical.
Organovo beats Omni Bio Pharmaceutical on 5 of the 9 factors compared between the two stocks.
Omni Bio Pharmaceutical Company Profile
Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.
Organovo Company Profile
Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Omni Bio Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omni Bio Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.